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Purpose: Gastrointestinal stromal tumor (GIST) has been considered radiation-resistant, and radiother-
apy is recommended only for palliation of bone metastases in current treatment guidelines. No registered
prospective trial has evaluated GIST responsiveness to radiotherapy.
Patients and methods: Patients with GIST progressing at intra-abdominal sites or the liver were entered to
this prospective Phase II multicenter study (identiﬁer NCT00515931). Metastases were treated with
external beam radiotherapy using either conformal 3D planning or intensity modulated radiotherapy
and conventional fractionation to a cumulative planning target volume dose of approximately 40 Gy.
Systemic therapy was maintained unaltered during the study.
Results: Of the 25 patients entered, 19 were on concomitant tyrosine kinase inhibitor therapy, most often
imatinib. Two (8%) patients achieved partial remission, 20 (80%) had stable target lesion size for
P3 months after radiotherapy with a median duration of stabilization of 16 months, and 3 (12%) pro-
gressed. The median time to radiotherapy target lesion progression was 4-fold longer than the median
time to GIST progression at any site (16 versus 4 months). Radiotherapy was generally well tolerated.
Conclusions: Responses to radiotherapy were infrequent, but most patients had durable stabilization of
the target lesions. GIST patients with soft tissue metastases beneﬁt frequently from radiotherapy.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 233–238
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Gastrointestinal stromal tumors (GIST) frequently give rise to
liver and intra-abdominal metastases. Imatinib, an inhibitor of
KIT, PDGFRA, and a few other kinases, is the standard ﬁrst-line
agent for metastatic GIST [1,2] with responses lasting for a few
years, but acquired drug resistance is frequent. Sunitinib is
approved for patients whose GIST is refractory to imatinib or
who do not tolerate imatinib [3], and regorafenib for those whose
disease does not respond to imatinib and sunitinib [4]. The median
time to GIST progression on sunitinib and regorafenib is 6 and
5 months, respectively [3,4]. Most patients with advanced GIST
will eventually receive palliative care.
Some retrospective data suggest that radiotherapy is not bene-
ﬁcial in the treatment of GIST [5], and GIST has been considered
radiotherapy-resistant or minimally responsive [6–9]. Current
treatment guidelines do not discuss radiotherapy as a therapeutic
option [1], or consider it only for palliation of rare bone metastases
[2]. However, results from a few case reports (reviewed in [10])
and a retrospective series with 15 patients [11] suggest thatadvanced GIST is not uniformly radioresistant and that selected
patients may beneﬁt from radiotherapy.
To our knowledge, no prospective study has investigated pallia-
tive radiotherapy as the treatment of GIST. We report here the ﬁrst
prospective trial addressing this patient population.Patients and methods
Study design
The study was a non-randomized, prospective multicenter trial.
Patients were registered centrally and reviewed for eligibility prior
to radiotherapy initiation. The primary endpoint was target lesion
response to radiotherapy. Secondary objectives included time to
progression (TTP) of the irradiated lesions, TTP of GIST at any site,
survival, and adverse effects associated with radiotherapy.Patients
Eligible patients had histologically veriﬁed inoperable GIST,
either locally advanced or metastatic disease. Tumor immunos-
taining for KIT was done in all cases as part of the diagnostic
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had been administered before study entry or that the patient did
not tolerate tyrosine kinase inhibitors, P1 GIST lesions were pro-
gressing during or after tyrosine kinase inhibitor therapy, and that
the target lesions selected for radiotherapy were measurable. We
excluded patients with World Health Organization (WHO) perfor-
mance status 4, pregnant women, and cases where radiotherapy
was not considered feasible due to infection, restlessness, or other
reasons, or if the planning target volume (PTV) deﬁned by the 90%
isodose [12] was >3000 cm3.
The study protocol (NCT00515931, www.ClinicalTrials.gov) was
approved by an Ethics Committee. Each patient provided written
informed consent prior to study entry.Procedures
External photon beam therapy was given with a linear acceler-
ator. Radiotherapy was administered as conformal 3-dimensional
(3D) radiotherapy or intensity-modulated radiotherapy (IMRT),
and planning was based on computerized tomography (CT). Use
of P2 portals was mandated. The clinical target volume (CTV)
encompassed the gross tumor plus a margin of approximately
1 cm. The planning target volume (PTV) encompassed the CTV plus
the margin required by target movement and dose fall-off, typi-
cally the CTV plus 0.5–1.0 cm. Radiotherapy was given in 1.8–
2.0 Gy daily fractions, 5 fractions weekly, to a cumulative PTV dose
of 30–40 Gy [12].
The World Health Organization (WHO) performance status,
symptoms, weight, and blood cell counts and biochemistry were
assessed and CT of the abdomen was done 62 weeks that preceded
initiation of radiotherapy, and these investigations were repeated 6
and 12 weeks, and 6 months after radiotherapy completion. The CT
scans were reviewed centrally for tumor response by a professional
radiologist. Adverse effects were graded according to the Common
Terminology Criteria for Adverse Events (CTCAE) v.3.0, and were
captured on structured forms at baseline and at the scheduled
follow-up visits.
Tyrosine kinase inhibitor therapy that was ongoing at study
entry was allowed to continue during the study, but we required
the dosing to be kept unaltered to allow reliable radiotherapy
response evaluation. Palliative medication and medication indi-
cated for other diseases but GIST were allowed.Statistical analysis
Treatment response was deﬁned either as complete response
(CR) or partial response (PR) by RECIST1.0 or as stabilized disease
(SD) for >12 weeks. Gehan 2-stage procedure was followed in sam-
ple size estimation. Chance of rejecting treatment response of 20%
was considered to be <0.05 (1-b 0.95) when 14 patients were
entered to the trial in the ﬁrst phase. IfP3 (21%) of the 14 patients
beneﬁtted from radiotherapy, 11 further patients were entered to
reach a maximum of 25 patients.
Response duration was calculated from the date of ﬁrst occur-
rence of response to the date of disease progression, death, or
the date of last follow-up. The duration of SD was calculated with
the Kaplan–Meier life-table method from the ﬁrst date of radio-
therapy to the date of target lesion progression or death, whichever
occurred ﬁrst, censoring patients alive without target lesion pro-
gression on the date of last follow-up. Time to GIST progression
was computed from the date of radiotherapy initiation to the date
of ﬁrst GIST progression at any site or death from any cause when
death preceded GIST progression, censoring patients who were
alive without progression on the last date of follow-up. Time to
radiotherapy target lesion progression was computed from the
date of radiotherapy initiation to the date of ﬁrst GIST progressionin the PTV or to death. Overall survival was calculated from the
date of radiotherapy initiation to the date of death censoring
patients alive.
The safety population included all registered patients.
Continuous distributions between groups were compared with
the Mann–Whitney U-test. Lesion densities at baseline and after
radiotherapy were compared with the Wilcoxon signed rank test.
Survival between groups was compared using the log-rank test.
The P values are 2-sided. The data were analyzed using a
Statistical Package for Social Sciences version 19.0 (SPSS Inc.,
Chicago, IL, USA).Results
Twenty-ﬁve patients were registered through January 29, 2008
and February 2, 2014 from 3 study sites (Table 1). All patients had
received imatinib prior to radiotherapy, and 15 (60%) also suni-
tinib. Ten (40%) patients had been treated withP3 tyrosine kinase
inhibitors before radiotherapy. None had received prior radiother-
apy for GIST, but 13 (52%) had surgery to remove metastases.
The patients had metastatic GIST. The sites of the lesions are
provided in Table 1. Twenty-one (84%) of the 25 patients had an
intra-abdominal tumor and 4 (16%) liver metastases as the target
lesions. Sixteen (64%) patients had 1 target lesion, 4 (16%) patients
had two, and 5 (20%) 3–5 target lesions. The median largest target
tumor diameter was 6.8 cm (range, from 2.4 to 14.5 cm). The med-
ian cumulative PTV dose was 39.6 Gy (range, from 30.0 to 40.0 Gy),
which was achieved in a median of 28 days using conformal 3D
planning (18 patients) or IMRT (7 patients). Six (24%) patients
did not receive tyrosine kinase inhibitors during radiotherapy,
whereas 19 (76%) were maintained on the prior systemic therapy
on which the radiotherapy target lesions had progressed (11
[44%] continued to receive imatinib, 4 [16%] sunitinib, 2 [8%] nilo-
tinib, 1 [4%] regorafenib, and 1 [4%] had a combination of sorafenib
and everolimus).
The median follow-up time was 19 months (range, from 2 to
74 months), and patients alive at the time of data collection closure
(September 2014, n = 7) were followed up for a median of
7 months (range, from 6 to 41 months). Twenty (80%) had GIST
progression during the follow-up, and 18 (72%) died.
Two (8%) patients achieved PR as the best response based on
central assessment, 20 (80%) had SD, and 3 (12%) progressed
within 3 months from radiotherapy. The objective response rate
(CR or PR) was thus 8% (95% CI, from 0% to 19%), and the clinical
beneﬁt rate (CR, PR, or SD) 88% (95% CI, from 75% to 100%). The
per cent longest diameter changes of the target lesions measured
3 months after radiotherapy as compared with the baseline diam-
eters are provided in Fig. 1.
One patient with PR had the target lesion excised surgically
3 months after starting radiotherapy, and the response of the sec-
ond patient with PR lasted for 10 months. The estimated median
duration for the PTV lesion stabilization in the subset of patients
who had SD as their best response to radiotherapy (n = 20) was
16 months (8 stabilizations were ongoing at the time of the analy-
sis 6 to 45 months after starting radiotherapy).
The median time to ﬁrst GIST progression at any site was
4 months (95% CI, form 1 to 7 months). The irradiated lesions pro-
gressed in 14 (58%) patients during the follow-up. The estimated
median time to target lesion progression was 16 months (95% CI,
from 5 to 27 months). Since GIST progressed in 14 (58%) out of
the 24 evaluable patients outside of the PTV before progressing
within the PTV, this frequently led to a change in systemic therapy.
As this confounds radiotherapy response duration evaluation, we
calculated also the time from radiotherapy initiation to either
GIST progression within the PTV or to a change in systemic
Table 1
Characteristics of the patients and the tumors.
Characteristic Median (range) Number
(%)
Age (years) 61.4 (19.7–86.5)
Gender
Male 17 (68)
Female 8 (32)
WHO performance status
0 9 (36)
1 12 (48)
2 4 (16)
Primary tumor site
Stomach 6 (24)
Small intestine 13 (52)
Colon/rectum 3 (12)
Other 3 (12)
Primary tumor mitotic count (per 50 HPFs) 24 (2–250)
Primary tumor mutation
KIT exon 11 10 (40)
KIT exon 17 2 (8)
KIT exon 9 2 (8)
PDGFRA exon 12 1 (4)
Wild type for KIT/PDGFRA 6 (25)
Not available 4 (16)
Adjuvant imatinib
Yes 5 (20)
No 20 (80)
Time from GIST diagnosis to detection of
metastases (years)
0.06 (0–8.1)
Metastatic sitesa
Liver 10 (40)
Intra-abdominal 19 (76)
Soft tissue 2 (8)
Bone 1 (4)
First-line agent for metastatic disease
Imatinib 23 (92)
Sunitinib 2 (8)
Highest dose of imatinib administered
400 mg/day 9 (36)
500–1000 mg/day 16 (64)
No. of systemic therapies prior to study entry
1 7 (28)
2 8 (32)
3–5 10 (40)
Systemic agents given prior to radiotherapyb
Imatinib 25 (100)
Sunitinib 15 (60)
Nilotinib 8 (32)
Sorafenib 8 (32)
Vatalanib 2 (8)
Regorafenib 1 (4)
Everolimus 1 (4)
Prior palliative surgery for metastases
Yes 13 (52)
No 12 (48)
Time from GIST diagnosis to start of
radiotherapy (years)
5.3 (0.8–26.4)
Time from detection of metastases to
radiotherapy (years)
3.5 (0.6–26.4)
Abbreviations: GIST = gastrointestinal stromal tumor; HPF = high power ﬁeld of the
microscope; PDGFRA = platelet-derived growth factor alpha gene; WHO = theWorld
Health Organization.
a One patient may have P1 metastatic sites.
b One patient may have received P1 systemic agents.
Fig. 1. A water-fall plot showing the changes in the longest target lesion diameters.
The per cents refer to the ratio of the diameters measured centrally from a CT scan
obtained 3 months after radiotherapy to the baseline diameter. Two patients with
progressive disease (PD) did not have a CT taken 3 months after radiotherapy
available; 5 tumors did not change in size.
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no PTV progression on the date of a change in systemic therapy
(n = 6). The estimated median time to target lesion progressionor to a change in systemic therapy was 12 months (95% CI, from
1 to 22 months). The median overall survival time was 19 months
(Fig. 2).
In the subset of patients with wild type GIST (n = 6) 2 patients
achieved PR, 2 had SD, and 2 progressed, and their median time
to target lesion progression was 11 months, which did not differ
signiﬁcantly from the rest of the patients (P = 0.260). Of the 6
patients who were not on tyrosine kinase inhibitor therapy during
radiotherapy 1 achieved PR and 5 had SD, and their median time to
target lesion progression was longer as compared with the 19
patients who received tyrosine kinase inhibitor therapy concomi-
tantly with radiotherapy (23 versus 11 months; P = 0.014). One of
the 4 patients with a liver lesion as the target achieved PR, and 3
had SD as their best response.
The effect of radiotherapy on target lesion density was studied
as an exploratory analysis in 16 patients with a total of 25 evalu-
able target lesions (9 patients were excluded from the analysis; 6
did not receive a contrast agent prior to each CT scan, and 3 had
PD prior to 3 months of follow-up). The target lesions were less
dense 3 months after starting radiotherapy as compared with the
baseline density (median, 36.1 versus 44.1 Hounsﬁeld units [HU],
respectively, P = 0.017).
None of the patients discontinued radiotherapy prematurely.
Transient diarrhea was the most frequent adverse event recorded,
and occurred in 13 (52%) of the 25 patients, followed by pain (44%),
nausea (36%), and fatigue (32%, Table 2). Most patients (84%) had
anemia. Adverse events were usually mild to moderate (grade 1
or 2), and only few patients had severe (grade 3) toxicity. One
patient treated with IMRT for a 7.6 cm progressive liver metastasis
to a cumulative dose of 39.6 Gy with 1.8 Gy daily fractions and
who was on sorafenib 400 mg/day developed grade 4 biliary tract
necrosis. No weight loss occurred between study entry and the ﬁrst
follow-up visit performed 6 weeks after completion of radiother-
apy (median weight, 69.5 kg and 73.0 kg, respectively, P = 0.167).Discussion
Only 2 patients achieved PR, which could be in keeping with the
contention that GISTs are radiation-resistant, but as many as 20 of
the remaining 23 patients had durable stabilization of the target
lesion size. Considering that the median time to GIST progression
at any site was only 4 months and the median survival time
19 months, the median time to radiotherapy target lesion
Fig. 2. Kaplan–Meier estimates of survival. (A) The time to radiotherapy target lesion progression; (B) time to target lesion progression or to a change in systemic therapy
(whichever occurred ﬁrst); (C) time to ﬁrst GIST progression at any site; (D) overall survival. Patients censored are indicated with a bar.
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trolled for most of the remaining life-time of the patients. The
patient population was typical of advanced GIST, except that 6
(24%) patients had wild-type GIST and 2 (8%) KIT exon 17 mutation.
These mutational subgroups may have been enriched in the study
population due to their limited responsiveness to tyrosine kinase
inhibitors [13].
Estimation of response duration to local treatments may be
confounded by systemic treatments even in heavily pretreated
patient populations. Therefore, we performed a survival analysis
where patients without progression within the PTV but progress-
ing elsewhere and having systemic therapy changed were censored
on the date of the therapy change. This produced a conservative
estimate for the radiotherapy-related duration of SD, but the esti-
mate was still relatively long with a median of 12 months. The
responses we report are also conservative and for radiotherapy
alone. One patient whose 10.8 cm metastasis decreased 18% in size
following radiotherapy qualifying for SD, but disappeared after
subsequent change in systemic therapy was thus reported as SD,
and not CR.
Imatinib enhances sensitivity to radiotherapy in selected cell
lines derived from various types of human cancer [14]. Most of
the patients received tyrosine kinase inhibitors duringradiotherapy, frequently imatinib, and, therefore, the efﬁcacy
achieved could result rather from the combined effects of radio-
therapy and tyrosine kinase inhibitors, and might be less with radi-
ation alone. Our ﬁndings might not support this hypothesis. The
median time to target lesion progression was longer in the subset
of patients who were treated with radiotherapy alone without con-
comitant tyrosine kinase inhibitors as compared to patients who
were on maintained tyrosine kinase inhibitors during radiation,
but this exploratory analysis was based on small patient numbers.
Radiotherapy was usually well tolerated. Pain of any grade was
recorded in 11 (44%) patients during or after radiotherapy, but 16
(64%) patients had pain at study entry suggesting that much of the
pain recorded was unrelated to radiotherapy. In contrast, diarrhea,
nausea and fatigue were recorded in 13 (52%), 9 (36%), and 8 (32%)
patients during or after radiotherapy but infrequently prior to
radiotherapy (2 patients had fatigue, 1 diarrhea, and 1 nausea at
study entry), suggesting that most of these adverse events were
caused by radiotherapy. Anemia was frequently recorded, but this
was more likely related to advanced GIST and tyrosine kinase inhi-
bitor therapy than to radiotherapy.
One patient developed biliary tract necrosis, which was the only
grade 4 adverse event observed. Tyrosine kinase inhibitors that
inhibit the VEGF receptors may be associated with radiotherapy
Table 2
Adverse events registered.*
Adverse event registered in two or more patients Maximum grade of severity registered
None Grade 1 Grade 2 Grade 3
N (%) N (%) N (%) N (%)
Diarrhea 12 (48) 10 (40) 1 (4) 2 (8)
Pain 14 (56) 5 (20) 3 (12) 3 (12)
Nausea 16 (64) 8 (32) 1 (4) 0 (0)
Fatigue 17 (68) 5 (20) 1 (4) 2 (8)
Vomiting 19 (76) 5 (20) 1 (4) 0 (0)
Hemorrhage 21 (84) 2 (8) 1 (4) 1 (4)
Dyspepsia/heartburn 21 (84) 4 (16) 0 (0) 0 (0)
Constipation 23 (92) 2 (8) 0 (0) 0 (0)
Radiation dermatitis 23 (93) 2 (8) 0 (0) 0 (0)
Blood cell counts & blood biochemistry
Anemia 4 (16) 12 (48) 7 (28) 2 (8)
Leukopenia 18 (72) 4 (16) 3 (12) 0 (0)
Thrombocytopenia 20 (80) 4 (16) 0 (0) 1 (4)
ALT increase 22 (88) 2 (8) 1 (4) 0 (0)
Alkaline phosphatase increase 15 (60) 9 (36) 1 (4) 0 (0)
Creatinine increase 13 (52) 9 (36) 3 (12) 0 (0)
Abbreviations: ALT = alanine aminotransferase.
* One grade 4 adverse event was recorded (biliary tract necrosis); no grade 5 (lethal) adverse events occurred.
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few Phase I and II trials suggest that concomitant administration of
sunitinib and radiotherapy is safe [17,18]. In a recent Phase II study
where sorafenib was administered both concomitantly and after
radiotherapy for advanced hepatocellular carcinoma, 35% of the
40 patients treated developed P2 grade hepatotoxicity, and 15%
had P3 grade hepatotoxicity, of which 3 incidents were fatal
[19]. These ﬁndings suggest that tyrosine kinase inhibitors that
inhibit the VEGF receptors are best used cautiously in patients irra-
diated for hepatic lesions.
We did not collect data about the quality of life, which is a lim-
itation. The study accrual time was relatively long, possibly reﬂect-
ing efﬁcacy of systemic treatments and the undeﬁned role of
radiotherapy for GIST during the study. In our experience, progres-
sion of only one or a few metastases during tyrosine kinase inhibi-
tors therapy is not uncommon in GIST.
Conventional fractionation and a modest cumulative dose were
selected to be studied in this palliative setting, but further studies
investigating other fractionation schemes and larger fraction sizes
are warranted. In a recent retrospective series 6 (35%) of the 15
patients with GIST metastases usually treated with ten 3 Gy frac-
tions with or without concomitant tyrosine kinase inhibitor ther-
apy responded to treatment [11]. Selective internal radiotherapy
with 90Y microspheres has been found effective in anecdotal cases
[13], and warrants further evaluation.
In sum, the results suggest that GIST metastases are moderately
radiosensitive, and frequently stabilize for several months with
radiotherapy. Radiotherapy appears to be a well-tolerated means
to palliate patients who have advanced GIST progressing at one
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